PFE Stock News 29.05 05/15/2014 13:55:39 Pfizer Inc (PFE)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pfizer Inc (PFE) 29.05 $PFE

Exosomes Common Link in Cancer Drug Development
ACCESSWIRE - 37 mins ago
Whitefish, MT / May 15, 2014 / The cancer drug business is ablaze lately as pharmaceutical companies of all sizes are targeting a multitude of mechanisms of action to develop what they hope to be the next blockbuster cancer therapy. Immuno-oncology programs, namely PD-1 and PD-L1 inhibitors, are being held in high regard as the next generation of cancer therapies as Roche (OTCQX: RHHBY) races towards an FDA decision with MK-3465 for patients with advanced melanoma who did not respond to Bristol-Myers Squibb's (NYSE: BMY) Yervoy. Roche is making headlines not just with MK-3465, releasing data ahead of the May 30 start of this year's American Society of Clinical Oncology (ASCO) meeting, showing that its immune therapy drug MPDL3280A shrunk tumors in 10 of 20 bladder cancer patients. Pfizer (NYSE: PFE) is looking to consolidate some of its developmental pipeline through potentially the biggest biotech acquisition in history, offering more than $100 billion to buy AstraZeneca (NYSE: AZN). AstraZeneca's MedImmune unit is partnered with Pfizer, working on development of an anti-CTLA-4 combination therapy. MedImmune expanded its pipeline this week by inking a pact with Incyte (NASDAQ: INCY) to couple its MEDI4736 with Incyte's INCB24360 in a PD-L1-targeting regimen.

Most active New York Stock Exchange-traded stocks
AP - 1 hr 23 mins ago
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:

Midday Glance: Pharmaceuticals companies
AP - 1 hr 23 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 1 p.m.:

American College of Physicians, CECity, and Pfizer collaborate to increase adult immunization rates
PR Newswire - Thu May 15, 10:27AM CDT
The American College of Physicians (ACP), CECity, and Pfizer Inc. (NYSE FE) have announced a new initiative designed to increase adult immunization rates by assisting physicians and other health care providers in strongly recommending appropriate vaccination and tracking adult immunization rates for quality measurement and improvement. The three organizations made the announcement during the annual National Adult Influenza and Immunization Summit meeting being held May 13-15 in Atlanta.

Early Glance: Pharmaceuticals companies
AP - Thu May 15, 9:34AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 10 a.m.:

Global PVA (Polyvinyl Alcohol) Drugs Market 2014-2018 with Actavis plc, Novo Nordisk A/S, Pfizer Inc. & Shionogi & Co. Ltd. Dominating
M2 - Thu May 15, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nd3bjw/global_pva_drugs) has announced the addition of the "Global PVA Drugs Market 2014-2018" report to their offering. Over the years, there has been a gradual increase in awareness about PVA. The acceptability of PVA drugs is expected to rise during the forecast period because of increasing public awareness about PVA and the need for treatment. This is expected to result in increasing drug penetration. The growth witnessed during the past was primarily because of the growing awareness among patients and physicians, which resulted in increased diagnosis and treatment rates. In the recent past, there have been several awareness and educational programs specifically targeting patients with PVA. For instance, Novo Nordisk, one of the prominent players of this market introduced the formation of GLAM to ignite the conversation on vaginal health in 2013. GLAM is basically an alliance that encourages women to discuss issues about the menopause and seek help. Thus, the increasing awareness and resultant higher treatment seeking rates for PVA are expected to contribute to the growth of the market during the forecast period. According to the report, the Global PVA Drugs market has substantial unmet needs. Currently, the market is not well served with the existing product options; therefore, there exists a significant opportunity for new vendors to capitalize on the market. The market has significant unmet needs in terms of low diagnosis rates, low levels of treatment seeking behavior among menopausal women, and safety concerns associated with ERT. Efficient and safe treatment options to meet the current demand are in the pipeline. Hence, there is huge potential for new entrants to grow by addressing the high unmet need of the market. Further, the report states that the patent expiries of major approved drugs will affect the market adversely and will slow down its growth during the forecast period. The shift toward lower priced drugs will lead to a drop in the market valuations for that drug, reducing the overall market value. The introduction of these low-cost drugs is likely to increase the competition in the market, thereby eventually reducing the price of key drugs. Key Vendors - Actavis plc - Novo Nordisk A/S - Pfizer Inc. - Shionogi & Co. Ltd. Other Prominent Vendors - ANI Pharmaceuticals Inc. - Bionovo Inc. - EndoCeutics Inc. - QuatRx Pharmaceutical Co. - PeP-Tonic Medical AB - Teva Pharmaceutical Industries Ltd. - Therapeutics MD Inc. - Upsher-Smith Laboratories Inc. Market Drivers/Challenges/Trends - Significant Unmet Need. - Increasing Number of Patent Expirations. - Increase in Awareness of PVA. For more information visit http://www.researchandmarkets.com/research/nd..._pva_drugs

GlycoMimetics Announces Presentation of Rivipansel Data in Pediatric Patients at American Society of Pediatric Hematology Oncology 27th Annual Meeting
Business Wire - Thu May 15, 8:03AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that data from a Phase 2 clinical trial of its lead drug candidate rivipansel (GMI-1070) in pediatric patients has been presented at the American Society of Pediatric Hematology Oncology (ASPHO) 27th Annual Meeting. As part of the symposium entitled, "Sickle Cell Disease: Saving the Brain and Treating the Pain," Timothy McCavit, M.D., M.S., Assistant Professor of Pediatric Hematology-Oncology at UT Southwestern Medical Center, highlighted the results observed in a randomized, multi-center, double-blind, adaptive Phase 2 study of rivipansel in pediatric sickle cell disease patients with vaso-occlusive crisis (VOC). The ASPHO Meeting is taking place May 14 through May 17 at the Palmer House Hilton in Chicago.

Why Pfizer's Huge Offer for AstraZeneca Actually Makes Sense
Bob Ciura, The Motley Fool - Motley Fool - Thu May 15, 6:00AM CDT
On the surface, offering $106 billion to take over a rival seems like nothing short of desperation. That's exactly what pharmaceutical giant Pfizer is doing, though, trying to acquire European competitor AstraZeneca . Pfizer has been through...

AstraZeneca sees deal hurdles
at Investor's Business Daily - Wed May 14, 5:40PM CDT
U.K. drugmaker AstraZeneca's (AZN) CEO, Pascal Soriot, on Wed. said he's open to talks with Pfizer (PFE) about a possible merger, but only if the price is right and certain risks are fully assessed, reports said. Soriot told Reuters he has concerns...

Final Glance: Pharmaceuticals companies
AP - Wed May 14, 5:13PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:

Exosomes Part and Parcel of Celldex, Pfizer, Incyte and More Cancer Targets
ACCESSWIRE - Wed May 14, 2:50PM CDT
Whitefish, MT / May 14, 2014 / Pharmaceutical companies big and small are targeting a multitude of mechanisms of action to develop what they hope to be the next blockbuster cancer therapy. Immuno-oncology programs, namely PD-1 and PD-L1 inhibitors, are receiving the praise of analysts as Roche (OTCQX: RHHBY) races towards an FDA decision with MK-3465. Shares of Celldex Therapeutics (NASDAQ: CLDX) are chugging ahead by 25 percent on Wednesday after striking a deal with Bristol-Myers Squibb (NYSE: BMY) to collaborate on the clinical development of BMY's PD-1 investigational drug nivolumab in combination with Celldex's CD27-targeting drug candidate varlilumab.

Dow Today: Pfizer (PFE) Higher
at The Street - Wed May 14, 12:00PM CDT
The Dow component leading the way higher looks to be Pfizer (NYSE: PFE ), which is sporting a two-cent gain to $29.22.

Health Care Sector Equities Technical Analysis -- Research on CombiMatrix, Quintiles Transnational Holdings, Pfizer, and GW Pharma
PR Newswire - Wed May 14, 10:26AM CDT
The trading session on Tuesday, May 13, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,715.44, up 0.12% and the NASDAQ Composite closed at 4,130.17, down 0.33%. The S&P 500 finished the day 0.04% higher at 1,897.45. During the trading session, six out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day 0.16% higher at 676.34, and the index has gained 0.84% in the previous three months. Investor-Edge has initiated coverage on the following equities: CombiMatrix Corp. (NASDAQ: CBMX), Quintiles Transnational Holdings Inc. (NYSE: Q), Pfizer Inc. (NYSE: PFE) and GW Pharmaceuticals PLC (NASDAQ: GWPH). Free technical research on CBMX, Q, PFE and GWPH can be downloaded upon signing up at:

Fitch Assigns an 'A+' Rating to Pfizer's Notes Offering
Business Wire - Wed May 14, 9:35AM CDT
Fitch Ratings has assigned an 'A+' rating to Pfizer Inc.'s (Pfizer's) $4.5 billion notes offering. Fitch expects Pfizer to use the net proceeds for general corporate purposes, including pre-funding the repayment at maturity of the EUR900 million outstanding of its 4.75% notes due December 2014 and pre-funding a portion of its outstanding 5.35% notes due March 2015. The rating action does not incorporate any effect from Pfizer's potential acquisition of AstraZeneca. The Rating Outlook is Stable. A full list of Pfizer's ratings is provided at the end of this release.

Research and Markets: Global Meningococcal Vaccines Market 2013 - 2019 - Polysaccharide, Conjugate, and Combination Vaccines, along with Pipeline Analysis
Business Wire - Wed May 14, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ft7dxb/meningococcal) has announced the addition of the "Meningococcal Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering.

Rep. Delaney Hopes Pfizer Anger Will Fuel Infrastructure Bill (Correction)
at The Street - Wed May 14, 9:31AM CDT
Anger over tax-driven megadeals has been reignited by Pfizer's proposed acquisition of AstraZeneca and Rep. John Delaney is hoping to harness that outrage to help build momentum for his trademark infrastructure legislation.

Athersys Reports Wider-than-Expected Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 14, 9:04AM CDT
Athersys, Inc.'s (ATHX) first quarter 2014 net loss of 15 cents per share was wider than the Zacks Consensus Estimate of a loss of 9 cents.

Next Support Level for Pfizer (PFE) is $28.93
Comtex SmarTrend(R) - Wed May 14, 9:00AM CDT
Pfizer (NYSE FE) has opened bearishly below the pivot of $29.23 today and has reached the first level of support at $29.07. Should the shares continue to fall, the support pivots of $28.93 and $28.63 will be of interest.

Global Meningococcal Vaccines Market 2013 - 2019 - Polysaccharide, Conjugate, and Combination Vaccines, along with Pipeline Analysis
M2 - Wed May 14, 8:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bwh98b/meningococcal) has announced the addition of the "Meningococcal Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The key players contributing to the global meningococcal vaccines market include Sanofi SA, Novartis AG, GSK plc, Pfizer, Inc., Nuron Biotech, JN International Medical Corporation, Serum Institute of India Ltd., Baxter International and Biomed Pvt. Ltd. The global meningococcal vaccines market is segmented broadly into polysaccharide, conjugate and combination vaccines. These vaccine types are further segmented into different brands available in the market. Polysaccharide vaccines is the oldest type available in market since last three decades. However, the presence and widespread use of conjugate vaccines has drastically reduced the incidences of bacterial meningitis due to the prolonged immunity achieved against the disease-causing serogroups, unlike polysaccharide vaccines which provide immunity for a very short period. Combination vaccines against invasive meningococci in combination with other organisms such as pneumococcal and Haemophilus influenzae type B are considered as new weapons to fight against two bacterial infections. This has shown to reduce the number of injections needed to be administered when compared to their individual doses. Hence, combination vaccines are likely to have high growth in forthcoming years. The notable pipeline vaccines against meningococcal disease include Bexsero by Novartis, MnB rLP2806 by Pfizer and NmVac4-DT by JN International Medical Corporation. Novartis in January 2013, received marketing authorization for Bexsero as the only vaccine against serogroup B, across the European Union, Canada and Australia, and has been currently filed for U.S. FDA licensure. The rLP2806 vaccine, is currently in phase III clinical trials and has been granted Breakthrough Therapy Status by the U.S. FDA in 2014. NmVac4 DT, on the other hand, has been developed against the broad range of (quadrivalent) serogroups A, C, Y and W-135. Moreover, its manufacturer of the vaccine JN International Medical Corporation claims the vaccine to be animal component free, which is expected to be the major driver for its demand post market launch. Major growth drivers for the global meningococcal vaccines market include favourable public-private partnerships to support development of vaccines at low cost, and the medical emergency status of the disease. Increase in the demand for vaccines and number of people getting immunized has been majorly contributed to the education and awareness campaigns conducted by manufacturers as well as non-profit organizations in the developed economies. Government intervention such as approval of legislations to mandate immunization programs for school children up to a certain age, and stringent regulations for Hajj pilgrims and sub-Saharan travellers also contribute positively to this market due to increased demand for these vaccines from the non-profit organizations. The global meningococcal vaccines market is segmented as follow: Companies Mentioned - Baxter International, Inc. - Biomed Pvt. Ltd. - GlaxoSmithKline plc - JN-International Medical Corporation - Novartis International AG - Nuron Biotech, Inc. - Pfizer, Inc. - Sanofi SA - Serum Institute of India Ltd. Polysaccharide Vaccines, by Brand - Menomune - Mencevax - NmVac4 - Others -- Quadri Meningo -- Bi Meningo Conjugate Vaccines, by Brand - Menactra - Menveo - NeisVac-C - Nimenrix - Meningitec - Menjugate - MenAfriVac Combination Vaccines, by Brand - MenHibrix - Menitorix Pipeline Vaccines, by Brand - Bexsero - MnB rLP2806 - NmVac4-DT For more information visit http://www.researchandmarkets.com/research/bw...ingococcal
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 50

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading

Top 5 Most Recently Viewed Articles

Luca Mining Welcomes New VP to Boost Corporate Development

Updated Category News Views 123

Luca Mining Corp. Strengthens Leadership Team Luca Mining Corp. (TSXV: LUCA) (OTCQX: LUCMF) is thrilled to announce a strategic addition to its team with the appointment of Mr. Adam Melnyk as Vice President of Corporate Development. This move is set to elevate the company’s business development initiatives and drive growth as it aims to expand its operations in the...

Continue Reading
Sapiens Powers Insurance Innovation at Global Client Conference

Updated Category News Views 149

Sapiens Hosts Global Client Conference to Transform Insurance This event unites insurance leaders to exchange ideas for growth, adaptability, and impactful business strategies. Sapiens International Corporation (NASDAQ: SPNS) recently held its annual International Client Conference, gathering insurance professionals, prospects, and partners for three days of insightful...

Continue Reading
Elon Musk's Rising Influence in Trump's Circles on Social Media

Updated Category News Views 174

Elon Musk's Transformation into a Political Influencer Elon Musk, renowned for his groundbreaking ventures, has recently emerged as a key advocate for former President Donald Trump. Through his platform X, formerly known as Twitter, Musk is significantly amplifying conservative viewpoints. A Shift in Political Engagement Musk’s political activity has noticed a marked...

Continue Reading
Enphase Energy's Earnings: A Potential Turnaround Amid Setbacks

Updated Category News Views 82

Enphase Energy's Earnings Anticipation Enphase Energy Inc. (NASDAQ: ENPH) is preparing to announce its third-quarter earnings. The anticipated earnings per share stand at 77 cents, with expected revenue reaching approximately $391.98 million. Despite these expectations, investor sentiment appears to be less than optimistic. This solar energy company has faced significant...

Continue Reading
Is the 'Sell America 2.0' Trend Resurfacing in the Market?

Updated Category News Views 120

Market Update: Examining Leadership Shifts As global yields rise, US megacaps face pressure as investors revisit the 'Sell America' strategy. Notably, the S&P 500 has recently broken important technical levels, with noticeable fatigue in tech, media, and telecom leadership. On the other hand, diversification appears to be paying off, as small caps, foreign equities, and...

Continue Reading